Cancer drug set for NHS fast-track
A new drug to treat advanced kidney cancer has been fast-tracked for use on the NHS, a health watchdog said yesterday.
The National Institute for Health and Clinical Excellence (Nice) is recommending Votrient (pazopanib). Pharmaceutical giant GlaxoSmithKline has agreed to a 12.5 per discount to the NHS, following the outcome of a clinical trial, comparing the drug with Sutent (sunitinib), which is already approved.
Dr Carole Longson, from Nice, said: "Pazopanib will offer patients an additional option and, for some, a more favourable side-effect profile."
Each year more than 8,000 new cases of kidney cancer are diagnosed in the UK, and almost half will lead to death.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies